Malignancy marker for therapy planning
- 总结
- Blood based test for an early classification of aggressive prostate cancers for personalized therapy planning.
- 技术优势
- Early classification of aggressive prostate cancers for personalized therapy planning.
Applicable for analyzing tissue samples and liquid biopsies.
Also relevant for other tumor entities (e.g. esophagus, breast cancer).
Additional biomarker that can be measured in an easy and objective way.
- 技术应用
- Prostate cancer diagnosis and classification, Therapeutic strategies
- 详细技术说明
- Vimentin 3 (Vim3) has been discovered as
biomarker, which correlates with the risk of
progression of prostate cancer. Results
show high expression of Vim3 in cells of
metastatic prostate and low expression in
non-metastatic cancer, thus demonstrating
the potential of Vim3 for risk stratification of
localized prostate carcioma to enable personalized therapy planning
- 合作类型
- Licensing
- 申请日期
- 02/10/2018 00:00:00
- 申请号码
- WO2018EP58923 20180406
- 分类
- - international:
G01N33/50
- cooperative:
G01N33/5091; G01N2800/367
- 其他
- Patent application
- ID号码
- 5158
- 国家/地区
- 德国
欲了解更多信息，请点击 这里
